Stimulation of suppressor cells in the bone marrow and spleens of high dose cyclophosphamide-treated C57Bl/6 mice

Cellular Immunology
D A NikcevichH T Wepsic


Systemic administration of a single dose (300 mg/kg) of cyclophosphamide (Cy) induced the appearance of a population of suppressor cells in the bone marrow and spleens of mice. Suppressor cells were assayed by their capacity to inhibit the concanavalin A (Con A) blastogenesis or the mixed-lymphocyte response of normal C57Bl/6 spleen cells. Cy-induced bone marrow (Cy-BM) suppressor cells were present as early as 4 days following Cy therapy and their activity gradually decreased over the next 2 weeks. Cy-induced splenic (Cy-Sp) suppressor cells were maximally present on Days 6 through 10 following Cy therapy. Studies were performed to characterize the suppressor cells of bone marrow obtained 4 days after Cy treatment and of normal bone marrow (N-BM). Some suppressor activity was present in normal bone marrow. N-BM suppressor cells resembled cells of the monocyte/macrophage lineage in that they were slightly adherent to Sephadex G-10, sensitive to L-leucine methyl ester (LME), and insensitive to treatment either with anti-T-cell antibody and complement or with anti-immunoglobulin antibody and complement. Their suppressive activity was abrogated by incubation with either indomethacin or catalase. Cy-BM suppressor cells were also re...Continue Reading


Nov 1, 1979·The Journal of Experimental Medicine·J J GoodwinR C Williams
Nov 3, 1977·The New England Journal of Medicine·J J GoodwinR C Williams
May 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·O J PlesciaK Grinwich
Aug 1, 1974·Journal of Immunological Methods·I A Ly, R I Mishell
Aug 1, 1982·Immunopharmacology·K R McIntoshD Segre
May 1, 1982·The American Journal of Anatomy·K Dorshkind, C Rosse
Feb 1, 1980·Cellular Immunology·J S CorveseS R Cooperband
Mar 15, 1981·Cellular Immunology·A M Fulton, J G Levy
Aug 1, 1981·Cellular Immunology·B F Argyris
Mar 1, 1980·Cellular Immunology·T J RogersD R Webb
Jan 1, 1980·Clinical Immunology and Immunopathology·J J Goodwin, D R Webb
Oct 1, 1986·Immunology Today·T MaierH N Claman


Feb 17, 2009·Current Oncology Reports·Jennifer S KoJames H Fincke
Feb 19, 1998·Zentralblatt für Veterinärmedizin. Reihe B. Journal of veterinary medicine. Series B·B Obmińska-DomoradzkaT Garbuliński
Jun 2, 2011·International Journal of Cancer. Journal International Du Cancer·Sari PesonenA Hemminki
Aug 9, 2008·International Immunopharmacology·Thomas DouglassM R Jadus
Oct 14, 2017·Immunological Reviews·Yuting MaHeng Yang
May 22, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·B PeláezJ L Subiza
Mar 1, 1994·The International Journal of Neuroscience·G MudòN Belluardo

Related Concepts

Catalase T
Hemolytic Complement
Cyclophosphamide, (S)-Isomer
Lymphocyte Activation
Mice, Inbred BALB C
Mice, Inbred C57BL

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.